Fungal Infection Due To Scedosporium Apiospermum — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for fungal infection due to scedosporium apiospermum. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
6
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Fungal Infection Due To Scedosporium Apiospermum

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sebela Ireland Ltd 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating fungal infection due to scedosporium apiospermum. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
28
5
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sporanox
itraconazole
 Sebela Ireland Ltd 6 55 — 2028-10-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8486456 Sporanox method of use 80 2028-10-03
10463740 Sporanox method of use 62 2033-06-21
9713642 Sporanox method of use 62 2033-06-21
9272046 Sporanox formulation 42 2033-06-21
8921374 Sporanox formulation 42 2033-06-21
10806792 Sporanox formulation 42 2033-06-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9272046 Sporanox formulation 42 2033-06-21
8921374 Sporanox formulation 42 2033-06-21
10806792 Sporanox formulation 42 2033-06-21
10463740 Sporanox method of use 62 2033-06-21
9713642 Sporanox method of use 62 2033-06-21
8486456 Sporanox method of use 80 2028-10-03

Related